Literature DB >> 12949496

The regulation of immunoglobulin E class-switch recombination.

Raif S Geha1, Haifa H Jabara, Scott R Brodeur.   

Abstract

Immunoglobulin E (IgE) isotype antibodies are associated with atopic disease, namely allergic rhinitis, asthma and atopic dermatitis, but are also involved in host immune defence mechanisms against parasitic infection. The commitment of a B cell to isotype class switch to an IgE-producing cell is a tightly regulated process, and our understanding of the regulation of IgE-antibody production is central to the prevention and treatment of atopic disease. Both those that are presently in use and potential future therapies to prevent IgE-mediated disease take advantage of our existing knowledge of the specific mechanisms that are required for IgE class switching.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12949496     DOI: 10.1038/nri1181

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  134 in total

1.  A novel (TG)n(GA)m repeat polymorphism 254 bp downstream of the mast cell chymase (CMA1) gene is associated with atopic asthma and total serum IgE levels.

Authors:  Shilpy Sharma; U Mabali Rajan; Amrendra Kumar; Abha Soni; Balaram Ghosh
Journal:  J Hum Genet       Date:  2005-05-28       Impact factor: 3.172

2.  Differences in the Importance of Mast Cells, Basophils, IgE, and IgG versus That of CD4+ T Cells and ILC2 Cells in Primary and Secondary Immunity to Strongyloides venezuelensis.

Authors:  Kaori Mukai; Hajime Karasuyama; Kenji Kabashima; Masato Kubo; Stephen J Galli
Journal:  Infect Immun       Date:  2017-04-21       Impact factor: 3.441

3.  Random allergen-specific IgE expression in atopic families: evidence for inherited "stochastic bias" in adverse immune response development to non-infectious antigens.

Authors:  Duaine R Jackola
Journal:  Mol Immunol       Date:  2007-01-23       Impact factor: 4.407

4.  Search for quantitative trait loci of atopy-associated immune responses using allergen-specific IgG1 as an "endophenotype".

Authors:  Duaine R Jackola; Michael B Miller; Carol L Liebeler; Malcolm N Blumenthal
Journal:  Hum Immunol       Date:  2007-09-07       Impact factor: 2.850

5.  DOCKing innate to adaptive signaling for persistent antibody production.

Authors:  Markus Werner; Hassan Jumaa
Journal:  Nat Immunol       Date:  2012-05-18       Impact factor: 25.606

6.  B cell-intrinsic and -extrinsic regulation of antibody responses by PARP14, an intracellular (ADP-ribosyl)transferase.

Authors:  Sung Hoon Cho; Ariel Raybuck; Mei Wei; John Erickson; Ki Taek Nam; Reagan G Cox; Alyssa Trochtenberg; James W Thomas; John Williams; Mark Boothby
Journal:  J Immunol       Date:  2013-08-16       Impact factor: 5.422

7.  Safety and efficiency of active immunization with detoxified antigen against scorpion venom: side effect evaluation.

Authors:  Nassrine Bachsais; Lila Boussag-Abib; Fatima Laraba-Djebari
Journal:  Inflamm Res       Date:  2017-05-17       Impact factor: 4.575

8.  IL-4-induced transcription factor NFIL3/E4BP4 controls IgE class switching.

Authors:  Masaki Kashiwada; Deborah M Levy; Lisa McKeag; Keri Murray; Andreas J Schröder; Stephen M Canfield; Geri Traver; Paul B Rothman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

9.  Heterodimeric Fc-fused IL12 shows potent antitumor activity by generating memory CD8+ T cells.

Authors:  Keunok Jung; Ji-Hee Ha; Jung-Eun Kim; Jeong-Ah Kim; Ye-Jin Kim; Chul-Ho Kim; Yong-Sung Kim
Journal:  Oncoimmunology       Date:  2018-03-06       Impact factor: 8.110

10.  Ouabain attenuates ovalbumin-induced airway inflammation.

Authors:  José Guilherme F M Galvão; Luiz Henrique Agra Cavalcante-Silva; Deyse Cristina M Carvalho; Laércia Karla D P Ferreira; Talissa Mozzini Monteiro; Adriano Francisco Alves; Larissa Adilis M P Ferreira; Francisco Allysson A F Gadelha; Marcia Regina Piuvezam; Sandra Rodrigues-Mascarenhas
Journal:  Inflamm Res       Date:  2017-09-13       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.